- Home
- HXL vs RNA Comparison
HXL vs RNA Comparison
Compare HXL & RNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HXL
- RNA
- Stock Information
- Founded
- HXL 1946
- RNA 2012
- Country
- HXL United States
- RNA United States
- Employees
- HXL N/A
- RNA N/A
- Industry
- HXL Major Chemicals
- RNA Biotechnology: Pharmaceutical Preparations
- Sector
- HXL Industrials
- RNA Health Care
- Exchange
- HXL Nasdaq
- RNA Nasdaq
- Market Cap
- HXL 5.2B
- RNA 4.4B
- IPO Year
- HXL N/A
- RNA 2020
- Fundamental
- Price
- HXL $63.52
- RNA $32.50
- Analyst Decision
- HXL Hold
- RNA Strong Buy
- Analyst Count
- HXL 14
- RNA 10
- Target Price
- HXL $71.62
- RNA $63.60
- AVG Volume (30 Days)
- HXL 782.9K
- RNA 1.1M
- Earning Date
- HXL 01-22-2025
- RNA 11-07-2024
- Dividend Yield
- HXL 0.94%
- RNA N/A
- EPS Growth
- HXL N/A
- RNA N/A
- EPS
- HXL 1.30
- RNA N/A
- Revenue
- HXL $1,886,700,000.00
- RNA $10,117,000.00
- Revenue This Year
- HXL $8.05
- RNA N/A
- Revenue Next Year
- HXL $8.59
- RNA N/A
- P/E Ratio
- HXL $49.05
- RNA N/A
- Revenue Growth
- HXL 7.14
- RNA N/A
- 52 Week Low
- HXL $57.50
- RNA $8.37
- 52 Week High
- HXL $77.09
- RNA $56.00
- Technical
- Relative Strength Index (RSI)
- HXL 53.41
- RNA 30.43
- Support Level
- HXL $63.27
- RNA $32.04
- Resistance Level
- HXL $64.70
- RNA $34.35
- Average True Range (ATR)
- HXL 1.49
- RNA 2.07
- MACD
- HXL 0.01
- RNA -0.55
- Stochastic Oscillator
- HXL 37.09
- RNA 6.24
About HXL Hexcel Corporation
Founded in 1948, Hexcel designs and manufactures a range of highly engineered composite fibers, fabrics, resins, and structures for use in commercial aerospace, defense, and other industrial markets. These are lighter than metal and perform under rigorous conditions in aircraft frames, wings, engines, and other components and subassemblies. The company's name derives from the six-sided honeycomb structures that lend many of its products their light weight and rigidity. Hexcel's biggest customers are Airbus (38% of 2022 sales) and Boeing (25% of prepandemic sales) and its respective subcontractors.
About RNA Avidity Biosciences Inc.
Avidity Biosciences Inc is a biotechnology company. The company develops novel Antibody Oligonucleotide Conjugates therapies designed to overcome the current limitations of oligonucleotide therapies in order to treat a wide range of serious diseases. Its product, AOC 1001, is designed to treat a rare monogenic muscle disease.